Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants: Results from the Dresden NOAC registry

Thrombosis and Haemostasis

Volumn 114, Issue 5, 2015, Pages 1076-1084

  Michalski, Franziska ^a   Tittl, Luise ^a   Werth, Sebastian ^a   Hänsel, Ulrike ^a   Pannach, Sven ^a   Sahin, Kurtulus ^b   Weiss, Norbert ^a   Beyer Westendorf, Jan ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b ClinStat GmbH   (Germany)

Author keywords

Anticoagulants; Atrial fibrillation; Bleeding; Outcome; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; VITAMIN K GROUP;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOEMBOLIC STROKE; DEATH; DISEASE REGISTRY; DRUG SAFETY; EMBOLISM; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SUDDEN CARDIAC DEATH; THROMBOEMBOLISM; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; DRUG SUBSTITUTION; GERMANY; HEMORRHAGE; MORTALITY; ORAL DRUG ADMINISTRATION; REGISTER; RISK; SURVIVAL ANALYSIS; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEMORRHAGE; HUMANS; MALE; PATIENT SELECTION; REGISTRIES; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VITAMIN K;

EID: 84946560492     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0116     Document Type: Article

References (28)

1. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129: 1155–1166.
2. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91–99.
3. Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725–733.
4. Steffensen FH, Kristensen K, Ejlersen E, et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242: 497–503.
5. Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26: 1149–1159.
6. Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Cmaj 2013; 185: E121–127.
7. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893–900.
8. Halbritter K, Beyer-Westendorf J, Nowotny J, et al. Hospitalization for Vitamin- K–Antagonist-related bleeding – treatment patterns and outcome. J Thromb Haemost 2013; 11: 651–659.
9. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
10. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.
11. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297.
12. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
13. Stollberger C, Finsterer J. Contra: „New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation“. Thromb Haemost 2013; 110: 496–500.
14. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from Vitamin- K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registry. Br J Clin Pharmacol 2014; in press.
15. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014; 35: 1888–1896.
16. Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955–962.
17. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694.
18. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975–983.
19. Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013; 127: 2166–2176.
20. Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014; 3: e000521.
21. Beyer-Westendorf J, Ebertz F, Forster K, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2015; 113: 1247–1257.
22. Amin A, Deitelzweig S, Jing Y, et al. Estimation of the impact of warfarin’s timein- therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis 2014; 38: 150–159.
23. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation 2014; Epub ahead of print.
24. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719–2747.
25. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6: 1500–1506.
26. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120: 700–705.
27. Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012; 172: 1687–1689.
28. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689–2696.